




Healthcare Industry News: La Jolla Pharmaceutical
News Release - March 5, 2010
La Jolla Pharmaceutical Announces Termination of Merger Agreement with Adamis Pharmaceuticals
SAN DIEGO--(HSMN NewsFeed)--La Jolla Pharmaceutical Company (Pink Sheets: LJPC ) today announced that La Jolla and Adamis Pharmaceuticals Corporation (OTCBB: ADMP ) have agreed to terminate their merger agreement relating to the proposed merger of the two companies. The termination follows La Jolla’s announcement on March 3, 2010, that its common stock would be suspended and delisted from The NASDAQ Stock Market (“Nasdaq”) effective at the open of business on March 4, 2010, and that its stockholders failed to vote in sufficient quantities for there to be a quorum to hold the stockholders’ meeting to approve the proposals related to the merger. Holders of only thirteen percent (13%) of La Jolla’s outstanding common stock had returned their proxy cards or otherwise indicated their votes prior to the start of the stockholders’ meeting. The meeting and the solicitation of further votes was canceled due to the delisting from Nasdaq.Immediately after Nasdaq suspended trading, the Company’s common stock began being quoted on the Pink OTC Markets Inc. (the “Pink Sheets”).
Source: La Jolla Pharmaceutical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.